Fmr LLC maintained its stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 4,391,885 shares of the biopharmaceutical company’s stock at the end of the first quarter. Fmr LLC owned approximately 10.61% of Fate Therapeutics worth $19,983,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the company. Creative Planning boosted its position in Fate Therapeutics by 35.3% in the first quarter. Creative Planning now owns 23,000 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6,000 shares in the last quarter. Hillsdale Investment Management Inc. bought a new position in Fate Therapeutics during the first quarter valued at about $160,000. TFS Capital LLC bought a new position in Fate Therapeutics during the first quarter valued at about $248,000. Bank of New York Mellon Corp boosted its position in Fate Therapeutics by 1.6% in the first quarter. Bank of New York Mellon Corp now owns 59,510 shares of the biopharmaceutical company’s stock valued at $271,000 after buying an additional 952 shares in the last quarter. Finally, Neuberger Berman Group LLC bought a new position in Fate Therapeutics during the first quarter valued at about $312,000. 60.46% of the stock is currently owned by hedge funds and other institutional investors.
Fate Therapeutics, Inc. (NASDAQ FATE) opened at 3.04 on Tuesday. The firm’s 50-day moving average is $3.41 and its 200 day moving average is $3.65. The stock’s market capitalization is $125.86 million. Fate Therapeutics, Inc. has a 52-week low of $1.55 and a 52-week high of $5.68.
Fate Therapeutics (NASDAQ:FATE) last posted its earnings results on Monday, May 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by $0.03. The firm had revenue of $1.03 million during the quarter, compared to analyst estimates of $1.04 million. Fate Therapeutics had a negative return on equity of 75.93% and a negative net margin of 857.34%. On average, equities analysts forecast that Fate Therapeutics, Inc. will post ($1.00) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Fmr LLC Holds Position in Fate Therapeutics, Inc. (FATE)” was posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://sportsperspectives.com/2017/07/18/fmr-llc-holds-position-in-fate-therapeutics-inc-fate.html.
Several research analysts have issued reports on FATE shares. HC Wainwright dropped their price target on Fate Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, March 20th. Wedbush reaffirmed an “outperform” rating and issued a $7.00 price target on shares of Fate Therapeutics in a report on Tuesday, May 16th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $6.25.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.